Combination treatment with the GPR30 specific antagonist G15 plus Tam induces both cytocidal action in vitro and antitumor progression in vivo. Thus, GPR30 might be a useful target in developing better treatments for TAM-R breast cancer patients. Here, GPER1 is linked to breast cancer.